Association between serum selenium status and prostate cancer risk in the EPIC-Heidelberg nested case-control study (n = 740)
Quartiles of serum selenium concentration (μg/L) | Continuous (per 10 μg/L) | ||||
---|---|---|---|---|---|
<78.9 | 78.9-87.0 | 87.0-95.0 | ≥95.0 | ||
Cases/controls (n) | 69/116 | 66/125 | 43/122 | 66/127 | |
Crude OR* (95% CI) | 1.00 | 0.90 (0.58, 1.40) | 0.60 (0.38, 0.95) | 0.89 (0.58, 1.37) | 0.92 (0.82, 1.04) |
Adjusted OR† (95% CI) | 1.00 | 0.92 (0.59, 1.43) | 0.61 (0.38, 0.98) | 0.78 (0.49, 1.22) | 0.89 (0.79, 1.01) |
Excluding cases diagnosed during 1st year of follow-up (and matched controls) | |||||
Cases/controls (n) | 68/112 | 59/116 | 40/117 | 64/119 | |
Adjusted OR† (95% CI) | 1.00 | 0.87 (0.55, 1.37) | 0.57 (0.35, 0.92) | 0.79 (0.50, 1.25) | 0.89 (0.78, 1.01) |
High-grade prostate cancer | |||||
Cases/controls (n) | 31/37 | 21/46 | 12/41 | 26/56 | |
Adjusted OR† (95% CI) | 1.00 | 0.53 (0.25, 1.12) | 0.34 (0.15, 0.79) | 0.50 (0.24, 1.03) | 0.84 (0.69, 1.02) |
Low-grade prostate cancer | |||||
Cases/controls (n) | 35/68 | 31/67 | 26/67 | 36/56 | |
Adjusted OR† (95% CI) | 1.00 | 0.91 (0.48, 1.71) | 0.75 (0.40, 1.41) | 1.10 (0.58, 2.09) | 0.96 (0.81, 1.15) |